

CARDIOBAND CLINICAL UPDATE

September 2016



Participating Sites



Study Demographics (N=50)

Variable	No. (%) or Mean
Age (years)	71 ± 8
Gender	Male 39 Female 11
Euroscore II (%)	7.5
Baseline NYHA Class of III or IV (%)	84
Ischemic **Non Ischemic**	31 19
LVEDD (mm) Avg±SD	61 ± 6
EF (%) Avg±SD	33 ± 11
Prev CABG **COPD** **Moderate to Severe Renal Failure** **Severe Pulmonary Hypertension** **Afib**	16 (32%) 11 (22%) 38 (76%) 12(24%) 39 (78%)

Reported Major Safety Events at 30 Days


30 Day Events*	Patients Experiencing Event, # (%) All Patients N=50
Death	2 (4%)
Hemorrhagic Stroke**	1 (2%)
Need for elective Mitral Operation**	1 (2%)
Ischemic attack	1 (2%)
Major Bleeding Complications	1 (2%)
Renal Failure	2 (4%)
Myocardial Infarction	0 (0%)
Respiratory Failure	0 (0%)
Cardiac Tamponade	1 (2%)

* VARC Guidelines (European Heart Journal, 2012, 33:2403-2414)

** Part of the Death case

One additional death case per ITT - compassionate


92% patients with MR≤2+ At 24 Months By Core Lab*




*Dr. Paul Grayburn – Baylor University


Annular Reconstruction by Significant Reduction in Septo Lateral (A-P) Dimension

30% average reduction in A-P








Septo Lateral (A-P) Dimension (mm) over time




Functional Improvement at 12 Months









Functional Improvement at 24 Months







Valtech



THANK YOU

www.valtechcardio.com